Bifunctional CDK9 Inhibitor Conjugates for Proteasomal Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases involving cyclin-dependent kinase 9 (CDK9) lack effective alternative strategies, with most inhibitors failing due to systemic concentration issues and the need for novel mechanisms of action.
Innovation Solution
Development of bifunctional compounds that recruit CDK9 to E3 ubiquitin ligases for targeted degradation, utilizing a Targeting Ligand to bind CDK9 and a Linker-Degron moiety to facilitate proteasomal degradation, thereby modulating CDK9 levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional CDK9 inhibitors are used, then CDK9 activity is inhibited, but the drugs fail to achieve high systemic concentrations and lack efficacy
Solution Approach 1:
The inhibitor is divided into two functional segments: a CDK9-targeting ligand portion and an E3 ligase-binding moiety portion, connected by a linker. This segmentation allows each segment to perform its specific function independently while working together to achieve targeted degradation, resolving the contradiction between achieving sufficient concentration and maintaining efficacy.
Solution Approach 2:
The bifunctional compound acts as an intermediary that bridges CDK9 and the E3 ubiquitin ligase system. By introducing this intermediary molecule, the patent enables targeted ubiquitination and degradation of CDK9, overcoming the limitations of conventional inhibitors that could not achieve both adequate systemic concentration and clinical efficacy.
2Reliability
If reversible CDK binders are used, then CDK activity is inhibited, but irreversible binders demonstrate superior performance
Solution Approach 1:
The patent merges reversible binding (CDK9-targeting ligand) with irreversible degradation (E3 ligase-mediated ubiquitination) into a single bifunctional mechanism. This combination achieves the reliability of irreversible binding while maintaining the selectivity and controllability of reversible binding, resolving the contradiction between efficacy and mechanism complexity.
3Quantity of substance
If most known CDK inhibitors are used, then CDK activity is blocked, but they fail in clinic trials due to insufficient systemic concentration
Solution Approach 1:
The bifunctional compound utilizes the cell's own ubiquitin-proteasome system to degrade CDK9, rather than relying on external accumulation of inhibitor molecules. This self-service mechanism bypasses the limitation of achieving sufficient systemic concentration, as the degradation is triggered locally at the target site, thereby improving both concentration availability and clinical applicability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bifunctional compounds demonstrate specificity and efficacy in degrading CDK9, offering a novel approach to treating diseases like cancer by effectively reducing CDK9 levels and overcoming resistance issues.
Implementation Method 1
The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases
Implementation Method 2
the proteins recognized by CRBN are ubiquitinated and degraded by proteasomes
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application provides bifunctional compounds of Formula (I): Targeting Ligand or a pharmaceutically acceptable salt, hydrate, solvate, prodrag, stereoisomer, or tautomer thereof, which act as protein degradation inducing moieties for cyclin-dependent kinase 9 (CDK.9). The present application also relates to methods for the targeted degradation of CDK9 through the use of th e bifunctional compounds that link a ubiquitin ligase-binding moiety to a ligand that is capable of binding to CDK9 which can be utilized in the treatment of disorders modulated by CDK9.